DGX vs. TAK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DGX and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
DGX is a standard domestic listing, while TAK trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | DGX | TAK |
|---|---|---|
| Company Name | Quest Diagnostics Incorporated | Takeda Pharmaceutical Company Limited |
| Country | United States | Japan |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 20.02 billion USD | 46.65 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | December 17, 1996 | January 5, 2010 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of DGX and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DGX | TAK |
|---|---|---|
| 5-Day Price Return | 2.74% | 2.78% |
| 13-Week Price Return | 1.79% | 5.93% |
| 26-Week Price Return | 10.08% | 5.75% |
| 52-Week Price Return | 19.03% | 5.51% |
| Month-to-Date Return | 6.95% | 3.74% |
| Year-to-Date Return | 18.68% | 4.21% |
| 10-Day Avg. Volume | 0.87M | 5.48M |
| 3-Month Avg. Volume | 1.22M | 4.67M |
| 3-Month Volatility | 23.63% | 15.38% |
| Beta | 0.56 | 0.42 |
Profitability
Return on Equity (TTM)
DGX
13.70%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
DGX’s Return on Equity of 13.70% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
TAK
1.48%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
TAK’s Return on Equity of 1.48% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Net Profit Margin (TTM)
DGX
9.03%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
A Net Profit Margin of 9.03% places DGX in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
TAK
2.36%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 2.36% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin (TTM)
DGX
14.02%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
An Operating Profit Margin of 14.02% places DGX in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
TAK
7.48%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
TAK’s Operating Profit Margin of 7.48% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | DGX | TAK |
|---|---|---|
| Return on Equity (TTM) | 13.70% | 1.48% |
| Return on Assets (TTM) | 5.94% | 0.72% |
| Net Profit Margin (TTM) | 9.03% | 2.36% |
| Operating Profit Margin (TTM) | 14.02% | 7.48% |
| Gross Profit Margin (TTM) | 33.23% | 65.51% |
Financial Strength
Current Ratio (MRQ)
DGX
1.09
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
DGX’s Current Ratio of 1.09 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
TAK
1.01
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
TAK’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
DGX
0.78
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
DGX’s Debt-to-Equity Ratio of 0.78 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TAK
0.65
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
TAK’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DGX
7.42
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
DGX’s Interest Coverage Ratio of 7.42 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
TAK
2.05
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 2.05 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | DGX | TAK |
|---|---|---|
| Current Ratio (MRQ) | 1.09 | 1.01 |
| Quick Ratio (MRQ) | 0.86 | 0.52 |
| Debt-to-Equity Ratio (MRQ) | 0.78 | 0.65 |
| Interest Coverage Ratio (TTM) | 7.42 | 2.05 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DGX
1.71%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
DGX’s Dividend Yield of 1.71% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
TAK
4.39%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.39%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
DGX
36.00%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
DGX’s Dividend Payout Ratio of 36.00% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
TAK
138.69%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
TAK’s Dividend Payout Ratio of 138.69% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | DGX | TAK |
|---|---|---|
| Dividend Yield (TTM) | 1.71% | 4.39% |
| Dividend Payout Ratio (TTM) | 36.00% | 138.69% |
Valuation
Price-to-Earnings Ratio (TTM)
DGX
21.05
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
DGX’s P/E Ratio of 21.05 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
TAK
63.81
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 63.81, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
DGX
1.90
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
DGX’s P/S Ratio of 1.90 is in the upper echelon for the Health Care Providers & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
TAK
1.50
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, TAK’s P/S Ratio of 1.50 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
DGX
2.77
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
DGX’s P/B Ratio of 2.77 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
TAK
1.01
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
TAK’s P/B Ratio of 1.01 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | DGX | TAK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 21.05 | 63.81 |
| Price-to-Sales Ratio (TTM) | 1.90 | 1.50 |
| Price-to-Book Ratio (MRQ) | 2.77 | 1.01 |
| Price-to-Free Cash Flow Ratio (TTM) | 16.34 | 9.71 |